2019 International Bladder Cancer Network

Viewing 1-20 of 24 articles

IBCN 2019: Transcriptomic Profiling of Bladder Cancer

IBCN 2019: Association of Immunohistochemical Markers Molecular Subtypes in Bladder Cancer

IBCN 2019: Genomic Classifier to Predict Luminal Bladder Tumors

IBCN 2019: Immunological Tumor Microenvironment in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy

IBCN 2019: Transcriptomic Data from a Cohort of Neuroendocrine Bladder Cancer Variant Histology Patients

IBCN 2019: Twenty-Year Experience of Outcomes from the Swedish National Registry of Urinary Bladder Cancer

IBCN 2019: Neoadjuvant Atezolizumab for cT2-4 N0 M0 Muscle-Invasive Bladder Cancer, A Phase II Trial

IBCN 2019: Non-Cisplatin Based Neoadjuvant Chemotherapy Agents for Cisplatin-Ineligible Patients Prior to Radical Cystectomy

IBCN 2019: The BLASST-1 Phase II Trial, the Efficacy and Safety of Nivolumab with Gemcitabine-Cisplatin - A Neoadjuvant Option for Patients with MIBC

IBCN 2019: Topography Analysis from Multispectral Imaging of the Immune Landscape in Bladder Cancer FFPE Specimens

IBCN 2019: Platinum-Based Neoadjuvant Chemotherapy on the Bladder Tumor Microenvironment

IBCN 2019: Molecular Subtyping in Patients with Muscle Invasive Bladder Cancer

IBCN 2019: Neoadjuvant Cisplatin-Based Chemotherapy on T Cell Phenotypes within the Sentinel Nodes of MIBC Patients

IBCN 2019: Multicenter Validation Study of Histopathologic “Tumor Regression Grading” Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

IBCN 2019: FGFR3 Mutations Investigated In an In Vivo Murine Model

IBCN 2019: Muscle-Invasive Bladder Cancer Novel Mouse Model Capable of Orthotopic Transplantation

IBCN 2019: TERT Promoter Mutations in Low-Grade Bladder Cancer Carcinogenesis

IBCN 2019: Molecular Characterization of Normal Ureteric Urothelium for More Meaningful Comparisons with Bladder Urothelium

IBCN 2019: The Synergistic Potential of BCG and STING Pathway Activators to Improve Response of Non-Muscle Invasive Bladder Cancer

IBCN 2019: Advanced Pathologic T1 Substaging to Improve the Identification of High-Risk Non-muscle Invasive Bladder Cancer Patients at Risk for BCG-Failure

1
2